Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
APVO 
Aptevo Therapeutics Inc (APVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: APVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $21
1 Year Target Price $21
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.71% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.42M USD | Price to earnings Ratio - | 1Y Target Price 21 |
Price to earnings Ratio - | 1Y Target Price 21 | ||
Volume (30-day avg) 1 | Beta 1.42 | 52 Weeks Range 1.04 - 298.00 | Updated Date 12/5/2025 |
52 Weeks Range 1.04 - 298.00 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1950.74 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-10 | When - | Estimate -2.09 | Actual -2.23 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -79.19% | Return on Equity (TTM) -242.74% |
Valuation
Trailing PE - | Forward PE 3.94 | Enterprise Value 6182681 | Price to Sales(TTM) 1.61 |
Enterprise Value 6182681 | Price to Sales(TTM) 1.61 | ||
Enterprise Value to Revenue 0.12 | Enterprise Value to EBITDA 0.39 | Shares Outstanding 16850494 | Shares Floating 16837014 |
Shares Outstanding 16850494 | Shares Floating 16837014 | ||
Percent Insiders 0.08 | Percent Institutions 2.94 |
Upturn AI SWOT
Aptevo Therapeutics Inc
Company Overview
History and Background
Aptevo Therapeutics Inc. was formed in 2016 as a spin-off from Emergent BioSolutions. It focuses on developing novel immunotherapies for oncology and hematology.
Core Business Areas
- ADAPTIR Platform: Aptevo's core technology platform for creating bispecific and multi-specific antibodies. This technology allows for creating customized therapeutic candidates.
- Hematology: Research and development of therapies for hematological malignancies.
- Immuno-oncology: Development of immunotherapies that harness the body's immune system to fight cancer.
Leadership and Structure
Marvin White is the President and CEO. The company has a typical biotech organizational structure with departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- Ruxience (biosimilar of Rituxan): Ruxience is a biosimilar of Rituxan (rituximab), indicated for the treatment of certain blood cancers and autoimmune diseases. Market share data is available through biosimilar market reports; competitors include other Rituxan biosimilars like Truxima and Riabni manufactured by Celltrion and Amgen respectively and the originator Rituxan.
- Apex-DUET: A bispecific antibody candidate in clinical development for the treatment of hematologic malignancies. No revenue currently. Competitors include companies developing bispecific antibodies like Regeneron and AbbVie.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, focusing on developing innovative therapies for unmet medical needs. Immuno-oncology and hematology are rapidly growing segments.
Positioning
Aptevo is a smaller player in the biotech industry, focusing on its ADAPTIR platform to develop novel bispecific antibody therapies. Their competitive advantage lies in their proprietary technology.
Total Addressable Market (TAM)
The TAM for bispecific antibodies and related immunotherapies is estimated to be in the billions of dollars. Aptevo is positioned to capture a share of this market through successful clinical trials and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary ADAPTIR technology platform
- Focus on innovative immunotherapies
- Experienced management team
- Potential for strategic partnerships
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Competition from larger pharmaceutical companies
- Ruxience Revenue share agreement with Emergent BioSolutions
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of ADAPTIR platform applications
- Positive clinical trial results
- Increasing demand for immunotherapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from biosimilars and novel therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- JNJ
- BMY
- MRK
- PFE
- ABBV
Competitive Landscape
Aptevo faces intense competition from larger pharmaceutical companies with greater resources and established pipelines. They must rely on their ADAPTIR platform to differentiate themselves.
Growth Trajectory and Initiatives
Historical Growth: Aptevo's growth has been dependent on revenue from Ruxience and progress in clinical trials.
Future Projections: Future growth is projected to be driven by the success of Apex-DUET and other candidates in development. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for Apex-DUET and seeking strategic partnerships.
Summary
Aptevo Therapeutics is a biotech company with a promising ADAPTIR platform, but it faces challenges due to limited financial resources and competition from larger players. The success of its clinical trials, especially Apex-DUET, is crucial for future growth. Strategic partnerships could provide needed capital and expertise. However, clinical trial failures or regulatory hurdles pose significant risks to the company's prospects.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Aptevo Therapeutics Inc. SEC Filings (10-K, 10-Q, 8-K)
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aptevo Therapeutics Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2016-07-20 | President, CEO & Director Mr. Marvin L. White | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | Website https://aptevotherapeutics.com |
Full time employees 37 | Website https://aptevotherapeutics.com | ||
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.